La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

CardieX Gestion

Gestion contrôle des critères 2/4

CardieX's CEO is Craig Cooper, appointed in Dec 2017, has a tenure of 6.67 years. total yearly compensation is A$1.50M, comprised of 42.2% salary and 57.8% bonuses, including company stock and options. directly owns 2.21% of the company’s shares, worth A$370.18K. The average tenure of the management team and the board of directors is 2.8 years and 6 years respectively.

Informations clés

Craig Cooper

Directeur général

AU$1.5m

Rémunération totale

Pourcentage du salaire du PDG	42.2%
Durée du mandat du directeur général	6.7yrs
Propriété du PDG	2.2%
Durée moyenne d'occupation des postes de direction	2.8yrs
Durée moyenne du mandat des membres du conseil d'administration	6yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Craig Cooper a-t-elle évolué par rapport aux bénéfices de CardieX?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Dec 31 2023	n/a	n/a	-AU$9m
Sep 30 2023	n/a	n/a	-AU$14m
Jun 30 2023	AU$1m	AU$631k	-AU$19m
Mar 31 2023	n/a	n/a	-AU$16m
Dec 31 2022	n/a	n/a	-AU$14m
Sep 30 2022	n/a	n/a	-AU$13m
Jun 30 2022	AU$1m	AU$608k	-AU$12m
Mar 31 2022	n/a	n/a	-AU$11m
Dec 31 2021	n/a	n/a	-AU$10m
Sep 30 2021	n/a	n/a	-AU$7m
Jun 30 2021	AU$1m	AU$529k	-AU$5m
Mar 31 2021	n/a	n/a	-AU$4m
Dec 31 2020	n/a	n/a	-AU$3m
Sep 30 2020	n/a	n/a	-AU$3m
Jun 30 2020	AU$911k	AU$447k	-AU$3m
Mar 31 2020	n/a	n/a	-AU$3m
Dec 31 2019	n/a	n/a	-AU$4m
Sep 30 2019	n/a	n/a	-AU$3m
Jun 30 2019	AU$851k	AU$419k	-AU$3m
Mar 31 2019	n/a	n/a	-AU$3m
Dec 31 2018	n/a	n/a	-AU$3m
Sep 30 2018	n/a	n/a	-AU$3m
Jun 30 2018	AU$392k	AU$226k	-AU$3m

Rémunération vs marché: Craig's total compensation ($USD1.00M) is above average for companies of similar size in the Australian market ($USD299.11K).

Rémunération et revenus: Craig's compensation has increased whilst the company is unprofitable.

PDG

Craig Cooper (60 yo)

6.7yrs

Titularisation

AU$1,495,699

Compensation

Mr. Craig R. Cooper, BEc., LLB (Hons), is the Co-Owner at C2 Ventures Pty Ltd. He is Co-Founder, Group CEO, MD & Executive Director of CardieX Limited. He was Co-Founder, CEO, MD & Executive Director of Ca...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Niall Charles Cairns	Co-Founder & Executive Chairman	6.7yrs	AU$1.02m	0.66% A$ 110.4k
Craig Cooper	Co-Founder	6.7yrs	AU$1.50m	2.21% A$ 370.2k
Ahmad Qasem	Chief Science & Research Officer	no data	AU$240.19k	0.0084% A$ 1.4k
Steven Kesten	Chief Medical Officer	3.7yrs	AU$240.53k	0% A$ 0
Mark Gorelick	Chief Product Officer	3.7yrs	AU$395.47k	0.038% A$ 6.3k
Catherine Liao	Chief Strategy Officer	1.9yrs	AU$385.31k	0% A$ 0
Douglas Kurschinski	Executive VP & Head of Global Sales for AtCor Medical Division	no data	AU$360.84k	pas de données
Sanjeev Bhavnani	Chief Clinical Officer	less than a year	pas de données	pas de données
Louisa Ho	Company Secretary	1.2yrs	pas de données	pas de données

2.8yrs

Durée moyenne de l'emploi

60yo

Âge moyen

Gestion expérimentée: CDX's management team is considered experienced (2.8 years average tenure).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Niall Charles Cairns	Co-Founder & Executive Chairman	6.7yrs	AU$1.02m	0.66% A$ 110.4k
Craig Cooper	Co-Founder	6.7yrs	AU$1.50m	2.21% A$ 370.2k
Randall Nelson	Independent Non-Executive Director	8.8yrs	AU$194.65k	0.0052% A$ 877.0
Harry Kim	Special Advisor	5.4yrs	pas de données	pas de données
Alberto Avolio	Member of Medical Advisory Board	no data	pas de données	pas de données
John Cockcroft	Member of Medical Advisory Board	2.2yrs	pas de données	pas de données
Charlie Taylor	Independent Non-Executive Director	less than a year	pas de données	pas de données

6.0yrs

Durée moyenne de l'emploi

60yo

Âge moyen

Conseil d'administration expérimenté: CDX's board of directors are considered experienced (6 years average tenure).

CardieX Gestion

Gestion contrôle des critères 2/4

Informations clés

Mises à jour récentes de la gestion

Less than half of directors are independent

CardieX Limited Appoints Charlie Taylor as an Independent Non-Executive Director, Effective 1 March 2024

CardieX Limited, Annual General Meeting, Nov 30, 2023

CardieX Limited Announces Resignation of Lesa Musatto as Independent Non-Executive Director

CardieX Limited Appoints Reid Yeoman as the Group's New Us Based Chief Financial Officer

Less than half of directors are independent

Recent updates

New major risk - Market cap size

Less than half of directors are independent

CardieX Limited Appoints Charlie Taylor as an Independent Non-Executive Director, Effective 1 March 2024

CardieX Limited has completed a Follow-on Equity Offering in the amount of AUD 4 million.

CardieX Limited has filed a Follow-on Equity Offering in the amount of AUD 7.62 million.

CardieX Limited, Annual General Meeting, Nov 30, 2023

CardieX Limited Announces Resignation of Lesa Musatto as Independent Non-Executive Director

Full year 2023 earnings released: AU$0.15 loss per share (vs AU$0.12 loss in FY 2022)

New minor risk - Financial data availability

CardieX Limited to Report Fiscal Year 2023 Results on Aug 31, 2023

CardieX Limited announced that it expects to receive AUD 2.3 million in funding

First half 2023 earnings released: AU$0.072 loss per share (vs AU$0.053 loss in 1H 2022)

CardieX Limited has completed a Follow-on Equity Offering in the amount of AUD 4.044413 million.

CardieX Limited Appoints Reid Yeoman as the Group's New Us Based Chief Financial Officer

CardieX Limited (ASX:CDX) acquired All the Assets of Blumio, Inc.

Less than half of directors are independent

CardieX Limited, Annual General Meeting, Nov 30, 2022

CardieX Limited Auditor Raises 'Going Concern' Doubt

Full year 2022 earnings released: AU$0.12 loss per share (vs AU$0.059 loss in FY 2021)

CardieX Limited has completed a Follow-on Equity Offering in the amount of AUD 1 million.

Full year 2022 earnings released: AU$0.11 loss per share (vs AU$0.064 loss in FY 2021)

CardieX Limited has completed a Follow-on Equity Offering in the amount of AUD 4.330001 million.

CardieX Limited Announces FDA 510(K) Submission for Conneqt Pulse Dual Blood Pressure and Arterial Health Monitor

FDA Update for CONNEQT Companion App of Cardiex Limited

CardieX Limited Announces Appointment of Lesa Musatto as an Independent, Non-Executive Director

Less than half of directors are independent

CardieX Submits FDA Application for its CONNEQT App

First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Global Health Technology Company CardieX and Mobvoi Launch a Revolutionary Heart Health Monitoring Smartwatch for Consumers

Full year 2021 earnings released: AU$0.006 loss per share (vs AU$0.005 loss in FY 2020)

Full year 2021 earnings released: AU$0.006 loss per share (vs AU$0.005 loss in FY 2020)

CardieX Launches CONNEQT™

What Can We Learn About CardieX's (ASX:CDX) CEO Compensation?

Shareholders Are Thrilled That The CardieX (ASX:CDX) Share Price Increased 169%

CardieX Limited Announces New Devices on Track for Launch in 2021

CardieX Limited Announces Executive Appointments

Have Insiders Been Buying CardieX Limited (ASX:CDX) Shares?

CardieX Limited, Annual General Meeting, Dec 11, 2020

CardieX Limited Limited Announces Commercial Partnership Agreement with Mobvoi for New Health Smartwatch

Full year earnings released - AU$0.0046 loss per share

Full year earnings released - AU$0.0046 loss per share

Analyse de la rémunération des PDG

PDG

Titularisation

Compensation

Équipe de direction

Durée moyenne de l'emploi

Âge moyen

Membres du conseil d'administration

Durée moyenne de l'emploi

Âge moyen